SELLAS Life Sciences Group, Inc. filed a Form 8-K on November 20, 2026, disclosing the pricing of an underwritten public offering of common stock and entry into an underwriting agreement dated November 18, 2026.
Key Highlights
- Offering size: 11,538,462 shares of common stock priced at $13.00 per share to the public.
- Overallotment option: Underwriters were granted a 30-day option to purchase up to 1,730,769 additional shares on the same terms.
- Expected net proceeds: Approximately $161.8 million, assuming full exercise of the overallotment option, after deducting underwriting discounts, commissions, and estimated offering expenses.
- Underwriters: J.P. Morgan Securities LLC and TD Securities (USA) LLC acted as representatives of the several underwriters.
- Expected closing: On or about November 20, 2026, subject to customary closing conditions.
- Registration basis: The offering is made under a shelf registration statement on Form S-3 (Registration Statement No. 333-294504), filed March 20, 2026, which became automatically effective upon filing.
SELLAS Life Sciences Enters Underwriting Agreement for November 2026 Public Offering
According to the filing, SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) entered into an underwriting agreement on November 18, 2026, with J.P. Morgan Securities LLC and TD Securities (USA) LLC as representatives of the several underwriters. The agreement covers the sale of 11,538,462 shares of common stock, par value $0.0001 per share, at a public offering price of $13.00 per share.
The company disclosed that it expects to receive net proceeds of approximately $161.8 million from the offering. That figure, as stated in the filing, includes proceeds from the underwriters' exercise in full of their option to purchase up to 1,730,769 additional Option Shares, and is calculated after deducting underwriting discounts and commissions and estimated offering expenses. The 30-day overallotment option was granted to the underwriters under the same terms as the primary offering shares.
The filing states that the offering is made pursuant to a shelf registration statement on Form S-3 (Registration Statement No. 333-294504), previously filed with the SEC on March 20, 2026, which became automatically effective upon filing. A final prospectus supplement was filed with the SEC on November 19, 2026. The underwriting agreement contains, according to the filing, "customary representations and warranties, agreements and obligations, conditions to closing and termination provisions," as well as mutual indemnification provisions covering certain liabilities, including those arising under the Securities Act of 1933, as amended. The filing was signed by John T. Burns, Senior Vice President and Chief Financial Officer.
What Was Disclosed
SELLAS Life Sciences Group disclosed the terms of an underwritten public offering of 11,538,462 shares at $13.00 each, with an overallotment option for up to 1,730,769 additional shares, and expected net proceeds of approximately $161.8 million assuming full option exercise.




Please wait processing your request...